with an analysis population in the base years of 491 038 persons aged 50 and older. Quarter-specific information about ICD-10 diagnoses and PD drug prescriptions from the inpatient and outpatient sectors was used to validate PD cases. Estimations were presented for two validation strategies relying on repeated PD diagnoses (SIa) and on one PD diagnosis followed by at least one PD drug prescription (SIb).
insurance, the "Allgemeine Ortskrankenkasse" (AOK). In Germany, about 70 million people are covered through statutory programs, onethird of whom are members of the AOK. The AOK covers more than 50% of the population of higher ages. 21 We drew two exclusive randomized samples in the first quarters of the years 2004 and 2007, each containing a size of 250 000 persons aged 50 and older, which was about 2% of all persons insured in the AOK. The AOK sample is almost representative in terms of sex, but does not represent the German population with regard to age because persons from the sample are older (Table S3) . AOK-insured persons as a whole are less educated and probably sicker than the German population. 22 We will consider this aspect more closely in the discussion part. After combining the data sets, data cleaning, and validation processes, we arrived at an analysis sample for the first quarter of the base years of 491 038 individuals. 
| METHODS
To increase the number of PD cases in our analysis sample, we combined the two time periods. All calculations refer to persons aged 50 and older and are performed for valid PD cases only, for 5-year-age groups x and for the two sexes separately. 
Germany.
Data access was legally approved by the Scientific Institute of the AOK (WIdO). The study is based on anonymized administrative claims data that never involved patients directly. Individual patients cannot be identified, and the analyses presented do not affect patients whose anonymized records were used.
| PD diagnosis
PD was identified based on the ICD-10 codes G20.0, G20.1, G20.2, and G20.9. We developed internal validation strategies to rule out false-positive diagnoses (Table 1 , Appendix S1, Figure S1 ). These validation strategies were based on the type of physician, repeated diagnoses, and medication. In the outpatient sector, we distinguished between physicians who were "neurologists/psychiatrists" (NP) and those who were not ("others").
For all strategies, first we included only those diagnoses internally marked as "verified" in the outpatient sector and as "discharge diagnosis" or "secondary diagnosis" in the inpatient sector. Secondly, we excluded persons from our prevalent or incident cases in case the last diagnosis in our longitudinal data was atypical parkinsonism. Finally, we developed eight validation strategies by combining diagnoses from different medical sectors using the following criteria:
"2 Quarters" requires a confirmative diagnosis in at least one further quarter or a second diagnosis by another physician in the same quarter. "Medication" uses at least one PD drug prescription during the complete follow-up (ATC N04B). In accordance with the guidelines of the GSN, physicians are recommended to call their patients with PD no later than every 6 months for follow-up examinations and to start the medical treatment as soon as possible. 20 Therefore, we present the results of two final validation strategies based on at least two PD diagnoses (SIa) and on at least one PD diagnosis followed by a PD drug prescription (SIb; for an in-depth discussion of all strategies, see Appendix S2).
| RESULTS
In the description of our results, we refer to the prevalence per 100 000 persons and to the incidence rate per 100 000 person-years at age 50 and older. For the sake of brevity, however, we shall omit the latter qualification.
| Prevalence
The Table S1 ). This is also true for the SIb strategy ( Figure 2 , Table S1 ) which resulted in a standardized prevalence of 820 (CI 815-824) for men and of 779 (CI 774-783) for women.
| Incidence
A total of 3994 (SIa) and 3623 (SIb) new cases had their onset of PD during the follow-up, leading to an standardized incidence rate of 229 (SIa; CI 223-236) and 192 (SIb; CI 186-198) new cases (Table   S2 ). The mean age of PD onset was 76.8 years according to the SIa strategy and 76.9 with regard to the SIb strategy. Figure 3 compares age-specific incidence rates of this study with previous studies. While incidence rates vary considerably between studies, our estimates are at the higher end. Turning to the age-and sex-specific rates, incidence rates nearly doubled every 5 years from age 50-54 until age 70-74 ( Figure 4 , 
| DISCUSSION
Using a data sample from the largest German public health insurance, we present age-specific figures of prevalence and incidence rates of PD for Germany. Until now, health claims data have not been widely used in the field of epidemiological research in Germany, and to our knowledge, this is the first study that has investigated PD using this type of data. Depending on the validation strategy, the total number Figure S1 ), the more patients we exclude from our analysis and consequently the lower the prevalence became, particularly for the oldest old. Our two final strategies result in comparatively similar age-specific prevalences and incidence rates; however, the gap increases with age. One may argue that at advanced ages patients with PD may be prescribed PD medication to a lesser extent than at younger ages, probably due to negative side effects or adverse interactions. 25 Age-specific prevalences and particularly incidence rates in this study were somewhat higher than those of the latest German study by Trenkwalder, Schwarz. 8 The GSN assumes prevalences close to ours; however, it should be noted that they use data from a collaborative European study rather than German data. 10 The age profile of nearly all studies consistently showed an increase in prevalences and incidence rates with age up to group 85-89 and a decline beyond this age. Compared to the other studies, our higher incidence rates may be explained by 1 the inclusion of the institutionalized population, which is missing in most other studies. In our study, 20%
of all patients with PD were living in nursing homes, allowing us to analyze PD up to the highest ages; 2 the over-representation of less educated and chronically ill persons in the AOK. 22 To quantify this overrepresentation of sick persons, we calculated death rates as an indicator of morbidity and compared them with death rates of the German population. As a result, age-specific death rates are higher (Table S4) . Thus, incidence rates of PD which start rising strongly at higher ages may only marginally affected; 3 the uncertainty of the diagnostic criteria of PD in claims data where more than half of all diagnoses were made by physicians who are not trained to detect PD.
Our incidence rates are higher than those of Blin, Dureau-Pournin 9 who also used claims data in France and different validation strategies based on ICD codes and drug prescriptions. In contrast to our approach, this French study required a PD diagnosis to be confirmed by two different physicians. Another definition of PD relies on at least three PD drug reimbursements over 1 year.
Age seems to be one of the main factors for the occurrence of PD.
Some studies, including our investigation, found a decline in incidence rates for the oldest old, [14] [15] [16] [17] [18] and others did not. [11] [12] [13] However, varying definitions and small sample sizes make comparisons difficult. 1 The highest age group in our study contains a substantial number of 3543 individuals with 55-87 prevalent cases at the base years and 42-46 incident cases during the follow-up, which makes analyses still reasonable.
The decline might be partly a consequence of diagnostic uncertainty. For instance, typical extrapyramidal signs of PD as tremors are often associated with Alzheimer's disease, leading to misdiagnoses. 25 In addition, affected people at older ages may never seek medical attention. 26 Finally, unobserved heterogeneity within a population leads to mortality selection and determines the proportion of PD and persons without PD in advanced ages in favor of the latter group.
27
We found sex differences in the occurrence of PD which are consistent with previous studies. 11, 12, 15, 28 Men may be at greater risk for 
Age
are not very likely in the case of PD because these diagnoses would lead to far reaching consequences in terms of medical treatment, physiotherapy, speech therapy, etc.
20
One advantage of using AOK data is the large size of the study population on a national basis; a second is the inclusion of the institutionalized population. In our study, 20% of all patients with PD were living in nursing homes, allowing us to analyze PD up through the highest ages. Finally, because the routine documentation of diagnoses is provided by physicians, self-selection, non-response, or interviewer bias can be ruled out. 30 
| CONCLUSION
Our results emphasize the present relevance of PD in Germany.
Regarding aging populations worldwide, the consequences at the individual and society levels will be intensified. Thus, it is essential to be aware of the recent and reliable epidemiological data of PD to obtain needs assessments and cost calculations, and to offer adequate care services. For a better understanding of PD in the future, it might be helpful to conduct investigations concerning potential risk factors and gather information about changes of PD over time.
